Literature DB >> 30208386

Development and Validation of a Prediction Model for Mortality and Adverse Outcomes Among Patients With Peripheral Eosinopenia on Admission for Clostridium difficile Infection.

Audrey S Kulaylat1, Erica L Buonomo2, Kenneth W Scully3, Christopher S Hollenbeak1,4, Heather Cook5, William A Petri2,6,7, David B Stewart8.   

Abstract

Importance: Recent evidence from an animal model suggests that peripheral loss of eosinophils in Clostridium difficile infection (CDI) is associated with severe disease. The ability to identify high-risk patients with CDI as early as the time of admission could improve outcomes by guiding management decisions. Objective: To construct a model using clinical indices readily available at the time of hospital admission, including peripheral eosinophil counts, to predict inpatient mortality in patients with CDI. Design, Setting, and Participants: In a cohort study, a total of 2065 patients admitted for CDI through the emergency department of 2 tertiary referral centers from January 1, 2005, to December 31, 2015, formed a training and a validation cohort. The sample was stratified by admission eosinophil count (0.0 cells/μL or >0.0 cells/μL), and multivariable logistic regression was used to construct a predictive model for inpatient mortality as well as other disease-related outcomes. Main Outcomes and Measures: Inpatient mortality was the primary outcome. Secondary outcomes included the need for a monitored care setting, need for vasopressors, and rates of inpatient colectomy.
Results: Of the 2065 patients in the study, 1092 (52.9%) were women and patients had a mean (SD) age of 63.4 (18.4) years. Those with an undetectable eosinophil count at admission had increased in-hospital mortality in both the training (odds ratio [OR], 2.01; 95% CI, 1.08-3.73; P = .03) and validation (OR, 2.26; 95% CI, 1.33-3.83; P = .002) cohorts in both univariable and multivariable analysis. Undetectable eosinophil counts were also associated with indicators of severe sepsis, such as admission to monitored care settings (OR, 1.40; 95% CI, 1.06-1.86), the need for vasopressors (OR, 2.08; 95% CI, 1.32-3.28), and emergency total colectomy (OR, 2.56; 95% CI, 1.12-5.87). Other significant predictors of mortality at admission included increasing comorbidity burden (for each 1-unit increase: OR, 1.13; 95% CI, 1.05-1.22) and lower systolic blood pressures (for each 1-mm Hg increase: OR, 0.99; 95% CI, 0.98-1.00). In a subgroup analysis of patients presenting without initial tachycardia or hypotension, only patients with undetectable admission eosinophil counts, but not those with an elevated white blood cell count, had significantly increased odds of inpatient mortality (OR, 5.76; 95% CI, 1.99-16.64). Conclusions and Relevance: This study describes a simple, widely available, inexpensive model predicting CDI severity and mortality to identify at-risk patients at the time of admission.

Entities:  

Mesh:

Year:  2018        PMID: 30208386      PMCID: PMC6414272          DOI: 10.1001/jamasurg.2018.3174

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  22 in total

1.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

Authors:  R A Deyo; D C Cherkin; M A Ciol
Journal:  J Clin Epidemiol       Date:  1992-06       Impact factor: 6.437

2.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.

Authors:  Jacques Pépin; Nathalie Saheb; Marie-Andrée Coulombe; Marie-Eve Alary; Marie-Pier Corriveau; Simon Authier; Michel Leblanc; Geneviève Rivard; Mathieu Bettez; Valérie Primeau; Martin Nguyen; Claude-Emilie Jacob; Luc Lanthier
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

3.  A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infection.

Authors:  Kevin W Garey; Zhi-Dong Jiang; Shashank Ghantoji; Vincent H Tam; Vaneet Arora; Herbert L Dupont
Journal:  Clin Infect Dis       Date:  2010-11-08       Impact factor: 9.079

4.  Clostridium difficile ribotype does not predict severe infection.

Authors:  Seth T Walk; Dejan Micic; Ruchika Jain; Eugene S Lo; Itishree Trivedi; Eugene W Liu; Luay M Almassalha; Sarah A Ewing; Cathrin Ring; Andrzej T Galecki; Mary A M Rogers; Laraine Washer; Duane W Newton; Preeti N Malani; Vincent B Young; David M Aronoff
Journal:  Clin Infect Dis       Date:  2012-09-12       Impact factor: 9.079

5.  Microbiota-Regulated IL-25 Increases Eosinophil Number to Provide Protection during Clostridium difficile Infection.

Authors:  Erica L Buonomo; Carrie A Cowardin; Madeline G Wilson; Mahmoud M Saleh; Patcharin Pramoonjago; William A Petri
Journal:  Cell Rep       Date:  2016-06-23       Impact factor: 9.423

6.  Predictors of Clostridium difficile infection-related mortality among older adults.

Authors:  Teena Chopra; Reda A Awali; Caitlin Biedron; Eileen Vallin; Suchitha Bheemreddy; Christopher M Saddler; Keith Mullins; Jose F Echaiz; Luigino Bernabela; Richard Severson; Dror Marchaim; Paul Lephart; Laura Johnson; Rama Thyagarajan; Keith S Kaye; George Alangaden
Journal:  Am J Infect Control       Date:  2016-07-14       Impact factor: 2.918

Review 7.  Risk factors for mortality in Clostridium difficile infection in the general hospital population: a systematic review.

Authors:  M G Bloomfield; J C Sherwin; E Gkrania-Klotsas
Journal:  J Hosp Infect       Date:  2012-06-22       Impact factor: 3.926

8.  Pathogenicity Locus, Core Genome, and Accessory Gene Contributions to Clostridium difficile Virulence.

Authors:  Brittany B Lewis; Rebecca A Carter; Lilan Ling; Ingrid Leiner; Ying Taur; Mini Kamboj; Erik R Dubberke; Joao Xavier; Eric G Pamer
Journal:  mBio       Date:  2017-08-08       Impact factor: 7.867

9.  Relationship between bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection.

Authors:  A Sarah Walker; David W Eyre; David H Wyllie; Kate E Dingle; David Griffiths; Brian Shine; Sarah Oakley; Lily O'Connor; John Finney; Alison Vaughan; Derrick W Crook; Mark H Wilcox; Tim E A Peto
Journal:  Clin Infect Dis       Date:  2013-03-05       Impact factor: 20.999

10.  The binary toxin CDT enhances Clostridium difficile virulence by suppressing protective colonic eosinophilia.

Authors:  Carrie A Cowardin; Erica L Buonomo; Mahmoud M Saleh; Madeline G Wilson; Stacey L Burgess; Sarah A Kuehne; Carsten Schwan; Anna M Eichhoff; Friedrich Koch-Nolte; Dena Lyras; Klaus Aktories; Nigel P Minton; William A Petri
Journal:  Nat Microbiol       Date:  2016-07-11       Impact factor: 17.745

View more
  20 in total

Review 1.  Considering the Immune System during Fecal Microbiota Transplantation for Clostridioides difficile Infection.

Authors:  Alyse L Frisbee; William A Petri
Journal:  Trends Mol Med       Date:  2020-02-17       Impact factor: 11.951

Review 2.  The Inflammasome and Type-2 Immunity in Clostridium difficile Infection.

Authors:  Alexandra Donlan; William A Petri
Journal:  Clin Colon Rectal Surg       Date:  2020-02-25

3.  External Validation and Comparison of Clostridioides difficile Severity Scoring Systems.

Authors:  D Alexander Perry; Daniel Shirley; Dejan Micic; Pratish C Patel; Rosemary Putler; Anitha Menon; Vincent B Young; Krishna Rao
Journal:  Clin Infect Dis       Date:  2022-06-10       Impact factor: 20.999

4.  Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study.

Authors:  Emma C Phillips; Cirle A Warren; Jennie Z Ma; Gregory R Madden
Journal:  Antimicrob Agents Chemother       Date:  2022-06-01       Impact factor: 5.938

5.  Aging Dampens the Intestinal Innate Immune Response during Severe Clostridioides difficile Infection and Is Associated with Altered Cytokine Levels and Granulocyte Mobilization.

Authors:  Lisa Abernathy-Close; Michael G Dieterle; Kimberly C Vendrov; Ingrid L Bergin; Krishna Rao; Vincent B Young
Journal:  Infect Immun       Date:  2020-05-20       Impact factor: 3.441

6. 

Authors:  L Klimek; S Becker; R Buhl; A M Chaker; T Huppertz; T K Hoffmann; S Dazert; T Deitmer; U Förster-Ruhrmann; H Olze; J Hagemann; S K Plontke; H Wrede; W Schlenter; H J Welkoborsky; B Wollenberg; A G Beule; C Rudack; S Strieth; R Mösges; C Bachert; T Stöver; C Matthias; A Dietz
Journal:  Laryngorhinootologie       Date:  2020-05-08       Impact factor: 1.057

7.  IL-33 drives group 2 innate lymphoid cell-mediated protection during Clostridium difficile infection.

Authors:  Alyse L Frisbee; Mahmoud M Saleh; Mary K Young; Jhansi L Leslie; Morgan E Simpson; Mayuresh M Abhyankar; Carrie A Cowardin; Jennie Z Ma; Patcharin Pramoonjago; Stephen D Turner; Alice P Liou; Erica L Buonomo; William A Petri
Journal:  Nat Commun       Date:  2019-06-20       Impact factor: 14.919

8.  Immune Profiling To Predict Outcome of Clostridioides difficile Infection.

Authors:  Mayuresh M Abhyankar; Jennie Z Ma; Kenneth W Scully; Andrew J Nafziger; Alyse L Frisbee; Mahmoud M Saleh; Gregory R Madden; Ann R Hays; Mendy Poulter; William A Petri
Journal:  mBio       Date:  2020-05-26       Impact factor: 7.867

9.  The Association between Peripheral Blood Cells and the Frailty Syndrome in Patients with Cardiovascular Diseases.

Authors:  Constantin Bodolea; Elisabeta I Hiriscau; Elena-Cristina Buzdugan; Alin I Grosu; Laurențiu Stoicescu; Ștefan Vesa; Omar Cauli
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2020       Impact factor: 2.895

10.  Systemic Inflammatory Mediators Are Effective Biomarkers for Predicting Adverse Outcomes in Clostridioides difficile Infection.

Authors:  Michael G Dieterle; Rosemary Putler; D Alexander Perry; Anitha Menon; Lisa Abernathy-Close; Naomi S Perlman; Aline Penkevich; Alex Standke; Micah Keidan; Kimberly C Vendrov; Ingrid L Bergin; Vincent B Young; Krishna Rao
Journal:  mBio       Date:  2020-05-05       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.